NEW YORK, March 15, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP) (Nasdaq:SGYPU) (Nasdaq:SGYPW), a developer of new drugs to treat gastrointestinal disorders and diseases, today reported its financial results for the fourth quarter and year ended December 31, 2011. Synergy is developing plecanatide for the treatment of chronic constipation (CC) and constipation-predominant irritable bowel syndrome (IBS-C).
